Insmed (INSM) Reports Q2 Loss of $0.72/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Insmed (INSM) Reports Q2 Loss of $0.72/Share

Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update

August 3, 2017 7:31 AM EDT

On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month  Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in the Second Half of 2017 U.S. Food and Drug Administration (FDA) Provides Established Name for Lead Development Program ALIS (amikacin liposome inhalation suspension)

BRIDGEWATER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) --  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet... More